Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Shares Purchased by Rhumbline Advisers

Rhumbline Advisers boosted its holdings in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) by 3.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 348,006 shares of the biotechnology company’s stock after acquiring an additional 10,041 shares during the quarter. Rhumbline Advisers owned about 0.22% of Ironwood Pharmaceuticals worth $1,542,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Pacer Advisors Inc. grew its stake in shares of Ironwood Pharmaceuticals by 4.0% in the fourth quarter. Pacer Advisors Inc. now owns 11,730,771 shares of the biotechnology company’s stock valued at $51,967,000 after buying an additional 450,949 shares in the last quarter. State Street Corp increased its position in Ironwood Pharmaceuticals by 7.3% in the 3rd quarter. State Street Corp now owns 9,919,865 shares of the biotechnology company’s stock valued at $40,870,000 after acquiring an additional 677,024 shares during the period. Charles Schwab Investment Management Inc. increased its position in Ironwood Pharmaceuticals by 23.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,904,271 shares of the biotechnology company’s stock worth $7,846,000 after purchasing an additional 364,841 shares during the period. Stonepine Capital Management LLC increased its position in Ironwood Pharmaceuticals by 1,982.8% during the 3rd quarter. Stonepine Capital Management LLC now owns 1,000,000 shares of the biotechnology company’s stock worth $4,120,000 after purchasing an additional 951,988 shares during the period. Finally, Royce & Associates LP boosted its stake in shares of Ironwood Pharmaceuticals by 10.8% during the 3rd quarter. Royce & Associates LP now owns 662,934 shares of the biotechnology company’s stock worth $2,731,000 after acquiring an additional 64,353 shares in the last quarter.

Insider Buying and Selling at Ironwood Pharmaceuticals

In other Ironwood Pharmaceuticals news, CMO Michael Shetzline sold 41,269 shares of the firm’s stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $1.76, for a total value of $72,633.44. Following the sale, the chief marketing officer now owns 554,007 shares in the company, valued at approximately $975,052.32. This trade represents a 6.93 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Thomas A. Mccourt sold 139,064 shares of the firm’s stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $1.76, for a total transaction of $244,752.64. Following the completion of the sale, the chief executive officer now owns 1,160,634 shares in the company, valued at $2,042,715.84. The trade was a 10.70 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 192,381 shares of company stock worth $338,591. 12.90% of the stock is owned by company insiders.

Ironwood Pharmaceuticals Price Performance

NASDAQ:IRWD opened at $1.49 on Wednesday. Ironwood Pharmaceuticals, Inc. has a 1-year low of $1.43 and a 1-year high of $9.55. The firm has a 50-day moving average of $3.03 and a two-hundred day moving average of $3.79. The stock has a market cap of $238.44 million, a P/E ratio of -49.67 and a beta of 0.37.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last issued its earnings results on Thursday, February 27th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.08). Ironwood Pharmaceuticals had a negative return on equity of 0.96% and a negative net margin of 0.65%. The business had revenue of $90.55 million during the quarter, compared to the consensus estimate of $93.85 million. As a group, equities analysts expect that Ironwood Pharmaceuticals, Inc. will post 0.1 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the company. Craig Hallum decreased their price target on Ironwood Pharmaceuticals from $10.00 to $8.00 and set a “buy” rating on the stock in a research note on Wednesday, January 22nd. JMP Securities dropped their price objective on Ironwood Pharmaceuticals from $23.00 to $14.00 and set a “market outperform” rating for the company in a report on Thursday, January 30th. Finally, StockNews.com downgraded Ironwood Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, February 28th. Four equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, Ironwood Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $8.60.

Ironwood Pharmaceuticals Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.